Habash M, 887
Haddix H, 1077
Haesen R, 786
Hall N, 76
Han SH, 119
Hanford KJ, 1221
Harmatz JS, 775
Harris RZ, 1189
Hartman LN, 30
Hashemi G, 454
Hassell A, 76
Hauptman JB, 41
Havrilla N, 1169
Hayashi N, 583
Hayashi S, 1085
Haynes S, 1151
Haytoglu T, 767
Heald D, 695
Hebert MF, 91
Helidonis E, 55
Heller GV, 1038
Heller HJ, 1151
Hendriks MG, 738
Heyen P, 147
Higuchi S, 583
Hilt M, 1062
Hinderliter AL, 418
Hiraga Y, 462
Hoke JF, 560
Holland S, 385, 495, 786, 941
Holwerda KJ, 738
Hopfgartner G, 703
Hopkins NK, 260, 805, 1277
Hörmann K, 1062
Hsyu P-H, 1184
Hu OY-P, 155
Huang G-M, 155
Huang S-M, 899, 1006
Humphrey GH, 1143
Humphries TJ, 927
Hunt TL, 76, 1044
Hursting MJ, 513
Hurvitz C, 1248

Iavarone L, 560
Ikeda Y, 462
Ingenito AJ, 547
Inglis AML, 1189
Ito MK, 86
Ito S, 454

Jackson A, 310
James LP, 1242
Jayesekera D, 1085
Jayewardene A, 1085
Jemal M, 155
Jeng J-J, 155
Jensen BK, 1044
Jones AB, 811
Jones RT, 619
Jonkman JHG, 480, 703
Jorkasky DK, 513, 855, 1189
Jubert C, 664
Jung D, 161, 505, 800
Jungbluth GL, 1277
Jusko WJ, 624, 685

Kantor E, 578
Kaplan B, 166, 715
Kappenberger L, 402
Karara AH, 172
Karol MD, 1283
Katlama C, 47
Keane WF, 927
Kearns GL, 613
Kellstein DE, 520
Khalilieh S, 911
Kharasch ED, 275, 664
Khattak S, 454
King SP, 30, 281
Kinoshita H, 583
Kinowski J-M, 721
Kirkesseli S, 480
Kirshner MA, 936
Kline WF, 385
Klockowski PM, 252, 297
Knorr B, 786
Knowlton P, 410
Koda RT, 268
Kodama H, 1070
Kodama Y, 1070
Komorowski-Swiatek D, 17
Kondo K, 462
Korecka M, 715
Koren G, 454
Korth-Bradley J, 729
Kotegawa T, 1256
Kotob F, 7
Koup JR, 410, 920
Kovacs SJ, 487
Kroboth PD, 327
Krøner K, 834
Kuhlmann J, 147
Kuranari M, 1070
Kustra R, 1184
Kutrzeba J, 826
Kwan D, 68
Kwon HM, 119

LaBoy-Goral L, 842
Lambrecht LJ, 1015
Langmuir V, 606
Larsen UL, 834
Larsen UT, 834
Larson P, 786
Lascoux C, 47
Lau H, 911
Laufen H, 1021
Laughton WB, 30, 281
Laurent AL, 593, 636, 911
Lee KB, 394
Lee P, 76
Legayada ES, 366
Lehmann DF, 533
Lentz G, 275
Lerner FE, 1053
Lesko LJ, 899, 1006
Levine A, 1248
Li WY, 268
Liao W, 155
Liboux AL, 480
Libutti SK, 394
Lim H-K, 1155
Lin JC, 86
Lin Y, 578
Liu A, 533
Lloyd P, 593
Lo A, 995
Locke CS, 1283
Loebstein R, 454
Loi C-M, 410, 920
Lowry RC, 192
Lush RM, 394
Luther RR, 471

MacAskill M, 155
Mahoney MC, 97
Mangoo-Karim R, 471
Marcus DB, 86
Marsh CL, 91
Martin DE, 487
Martin PT, 670, 945
Martin RR, 47
Matsuki S, 1256
Mattinger C, 1062
Mautz D, 275
Mayer PR, 945
Mayersohn M, 817
McConnaughey JS, 547
McConnaughey MM, 547
McConnaughey S, 547
McCormick GC, 30, 281
McCrea J, 1212
McCune TR, 310
McDonald J, 1233
McGill CC, 1038
McGoldrick K, 729
McIntosh TS, 487
McLeane LR, 180
McLeod JF, 172, 911
Meadowcroft AM, 418
Mechlinski W, 76
Meier-Kriesche HU, 166, 715
Mekki Q, 1032
Mendelson JE, 619
Menendez AA, 1242
Messinger Y, 1248
Meyer J, 703
Michalodimitrakis M, 55
Michiels N, 786
Miller AK, 855, 1189
Miller-Stein C, 1212
Mis SM, 624
Mistry GC, 636
Miyakawa H, 119
Modi NB, 675
Mohammand Z, 767
Montay G, 480
Moore KHP, 593
Moraes MEA, 1053
Moraes MO, 1053
Morreale AP, 86
Morris DM, 593
Moyna NM, 1038
Mück W, 147
Mulgaonkar S, 715
Müller GA, 147
Mulligan TE, 41
Musson DG, 192
Myers DE, 1248

Nakamura K, 1256
Nakano S, 1256
Nakashima M, 462
Nath RP, 619
Nesbitt JD, 1272
Newman N, 533
Nguyen HH, 786
Nicholls PJ, 1136
Nishimoto M, 462
Nix DE, 855
Noonan G, 786
Norton J, 685
Novotny W, 675

O'Brien CP, 1221
O'Byrne PM, 230
Odeh M, 1290
Oesterheld JR, 775
Ogle CW, 448
Ojemann LM, 578
Oliven A, 1290
Olson SC, 501
O'Mara MJ, 593
O'Neill K, 1248
Ono S, 1070
Orgul O, 794
Osborne B, 1212
Osborne S, 911
Ovesen J, 834

Page CP, 237
Pak CYC, 1151
Pakes GE, 593
Parekh, N, 1263
Paritsis N, 55
Parker V, 1155
Parmelee DX, 775
Patterson JH, 418
Patterson S, 1189
Paul JC, 945
Pearson LK, 260
Pearson PG, 260
Peeters PAM, 480

Peng L, 513
Pesco-Koplowitz L, 76
Peters GR, 260
Phelps SJ, 359
Pieniaszek HJ, 817
Pieper JA, 418
Pierce CH, 223
Pittenger AL, 327
Pollock BG, 936
Pool JL, 471
Porras AG, 385
Powell JH, 1272
Preston GC, 560
Prueksaritanont T, 1212
Psillakis T, 55
Punn R, 310

Quan H, 385

Radwanski E, 1015
Randinitis EJ, 920, 1143
Rao A, 1248
Reece PA, 934
Reed E, 394
Reid G, 887
Reimann JD, 675
Reinhart RJ, 817
Reiss TF, 786
Reynolds K, 899
Rhodes GR, 661
Riedel K-D, 1021
Risner ME, 373
Robbins R, 651
Rogers JD, 786
Rohatagi S, 661
Roth-Schechter BF, 184
Rowan J, 131
Russell T, 349
Ryan KK, 805

Sahajwalla C, 899
Sainati SM, 184
Salazar DE, 685
Salek FS, 327
Sallee FR, 775
Sathyan G, 289
Sattler FR, 268
Sauron R, 811
Scharpf F, 1021
Schechter PJ, 47
Scheel PJ, 125, 794
Schelling A, 738
Schentag JJ, 855
Schmage N, 147
Schmidt BMW, 1062
Schmitt R, 703
Schmucker DL, 1103
Schulz R, 847
Schumacher T, 1021
Schwed A, 402
Sedman AJ, 410, 920, 934
Seibold JR, 1077
Seidenberg BC, 786
Seligmann H, 1290
Senn T, 275, 664
Séréni D, 47
Shabib S, 366
Shader RI, 775
Shadle CR, 192
Shah A, 1085
Shah B, 695, 1044
Shah J, 606
Shahane A, 941
Shapiro MA, 1143
Sharma A, 685
Shaw LM, 715
Shaw S, 593
Sheth SB, 513
Shine D, 1233
Shwonek P, 619
Siedlik PH, 501
Simcoe D, 30, 281
Sisson TL, 1277
Slutsky AS, 246
Smith CM, 97
Smith R, 76, 155
Smith S, 310
Sorisio DA, 936
Spielberg S, 786
Stack JA, 936
Stansell JD, 268
Staunstrup H, 834
Stern R, 410, 501
Sterna R, 826
Sterrett AT, 636
Stewart A, 1151
Stolley SN, 86
Stowe CD, 359, 1242
Sturgill MG, 1077
Sulżyc-Bielicka V, 826
Swan SK, 927, 1015

Tahara M, 131
Tammara B, 1177
Taulera O, 47
Taylor AA, 471
Taylor KP, 252, 297
Teitelbaum P, 505
Teo SK, 1162
Thevanayagam L, 1085
Thomas SD, 1162
Thompson DS, 936
Thompson GA, 1272
Thompson KA, 1189
Thompson PD, 1038
Thummel KE, 664
Timmer W, 1062
Tournerie C, 47
Townley RG, 210
Tran JQ, 487, 513
Travers S, 76
Troullos E, 131
Troy SM, 670
Tsanaclis LM, 934
Tsatsakis AM, 55
Tse S, 670
Tsutsumi K, 1070, 1256
Tubiana R, 47
Tucci M, 513

Uckun FM, 1248
Uderman HD, 685
Umemura K, 462
Upton RA, 619

Valentine SN, 1263, 1272
Van Belle SJP, 385
van der Sluijs J, 738
van der Vring JA, 738
Van Hecken A, 495, 941
van Marle S, 703
van Nispen CHM, 786
Vassos AB, 410, 920
Venkatakrishnan K, 567
Venzon DJ, 394
Verbesselt R, 495, 941
Vesell ES, 1103
Viischer HW, 703
von Moltke LL, 567
Vormfelde SV, 147
Vyas KP, 385

Waeber B, 402
Wagner DL, 1272
Waksman JA, 520
Waldman S, 1212
Walker SE, 68
Wallace M, 180
Watson J, 180
Weber C, 703, 847
Wedel N, 1169
Wehling M, 1062
Wei GCG, 842
Wemer J, 480
Wheeler S, 670
White CM, 111, 442, 1038
White K, 180
White M, 1169
Wienkers LC, 260
Wiesinger B, 76
Wilensky AJ, 578
Williams M, 1263
Williams PB, 310
Williams RL, 1006
Williamson KM, 418
Withagen AJ, 738
Wójcicki J, 826
Wolpin J, 454
Womble GP, 373
Wombolt DG, 310
Wong PH, 495
Wong YN, 30, 281
Wroe SJ, 934
Wu PC, 394
Wu Q, 794
Wurst W, 1062
Wylie M, 936
Wynants K, 495, 941

Xu X, 786

Yacoub L, 945
Yang B-B, 501
Yang BC, 155
Yeates R, 1021
Yeh KC, 1077
Yoshida Y, 462
Young B, 501
Yu DK, 1203
Yuan R, 899, 1109
Yukawa E, 583
Yusuf A, 366

Zannikos PN, 1044
Zariffa N, 855
Zarycranski W, 252, 297
Zhang KE, 385
Zhao J, 786
Zhi J, 41
Zhou H, 76, 911
Zimmerman JJ, 1155
Zimmermann T, 1021
Zwinderman AH, 738

Subject Index, Volume 39 (1999)

An "A" preceding a page number indicates an abstract

Acetaminophen
the effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin, 68

Adenosine AMP 579
pharmacokinetics, safety, and tolerability of single intravenous infusions of adenosine agonist AMP 579, in healthy male volunteers, 1044

Adrenal interactions
pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers, 624

Adverse effects
association of opportunistic infections with the occurence of rimethroprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus, 533

safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis, 520

severe life-threatening hyponatremia during paroxetine therapy, 1290

Age. *See also* **Geriatric; Pediatrics**
no effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy, 1070

open-label single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects, 281

AIDS. *See* **HIV**

Alendronate
pharmacokinetics of intravenous alendronate, 385

Alfentanil
intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance, 664

Alprazolam
pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam, 1109

Amikacin
pharmacokinetic changes of theophylline and amikacin through the menstrual cycle in healthy women, 1256

Amino terminals
pharmacokinetics of a recombinant modified amino terminal fragment of bactericidal/permeability-increasing protein ($rBPI_{21}$) in healthy volunteers, 1169

Aminoglutethimide
pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients, 1136

Analgesia
efficacy and tolerability of !ornixicam versus tramadol in postoperative pain, 834

pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery, 729

analgesic efficacy and pharmacokinetics of ketoprofen administered into a surgical site, 131

Angiotensin receptor blockers
practical considerations of the pharmacology of angiotensin receptor blockers, 547

Antihyperalgesic effects
antihyperalgesic effect of the N-methyl-D-asparate receptor antagonist dextromethorphan in the oral surgery model, 139

Argatroban
assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban, 513

Asthma
are new asthma therapies needed?, 230

asthma therapy from the practice perspective:changes in the wind, 223

genetics of asthma:from chicken soup to Napoleon to Toronto, 246

pharmacologic therapy for asthma:overview and historical perspective, 216

recent advances in our understanding of the use of theophylline in the treatment of asthma, 237

role of common cold in asthma, 241

Attention-deficit hyperactivity disorder
population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder, 775

Avitriptan
pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects, 685

Azimilide
azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation, 1272

Azimilide dihydrochloride
pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride, 1263

Azithromycin
effect of azithromycin on the pharmacokinetics of indinavir, 842

Aztreonam
a pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam, 1277

Bisphosphonates
developments in the therapeutic applications of bisphosphonates, 651

Blocking drugs
alpha-adrenergic blocking drugs in clinical medicine, 7

Bosentan
effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin, 847

multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers, 703

Buprenorphine
buprenorphine pharmacokinetics:relative bioavailability of sublingual tablet and liquid formulations, 619

Bupropion
lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion, 1184

Caffeine
effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine, 252

frequency of caffeine withdrawl in a population-based survey and in a controlled blinded pilot experiment, 1221

inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women, 936

salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases, 366

Calcium
combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris:beneficial effect of calcium channel blockers largely determined by their effect on heart rate, 738

pharmacokinetics of calcium absorption from two commercial calcium supplements, 1151

the pharmacokinetics of extended-release formulations of calcium antagnoists and amlodipine in subjects with different gastrointestinal transit times, 1021

Cancer
pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients, 1136

Carbamazepine
carbamazepine levels in head hair of patents under long-term treatment:a method to evaluate the history of drug use, 55

Cardiac issues
assessment of QTc prolongation for non-cardiac-related drugs from a development perspective, 349

combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate, 738

a review of potential cardiovascular uses of intravenous glucagon administration, 442

CD19 receptor
clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies, 1248

Cerivastatin
pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance, 147

Ciclesonide
the new topical steroid ciclesonide is effective in treatment of allergic rhinitis, 1062
Cimetidine
the effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline, 855
lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion, 1184
Cisapride
lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults, 945
Cisplatin
pharmacokinetics of cisplatin administered by continuous hyperthermic peridoneal perfusion (CHPP) to patients with peritoneal carcinomatosis, 394
Clinafloxacin
pharmacokinetics of clinafloxacin enantiomers in humans, 1143
Clindamycin
systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream, 805
Clinical trials
combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris:beneficial effect of calcium channel blockers largely determined by their effect on heart rate, 738
the new topical steroid ciclesonide is effective in treatment of allergic rhinitis, 1062
Clozapine
clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia, 721
a clozapine overdose with markedly elevated serum levels, 97
CMV. *See* **Cytomegalovirus**
Contraceptive agents
effect of troglitazone on the pharmacokinetics of an oral contraceptive agent, 410
Coronary syndrome
pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome, 675
Cortisol
differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between Asian and Caucasian women, 578
Creatinine
pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance, 147
Cyclosporine
case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin, 310
effects of glucocorticoids and cyclosporine on IL-2 and IκBα mRNA expression in human peripheral blood mononuclear cells, 119
lymphocyte suppression by glococorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid, 125
CYP1A2
effect of vanlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine, 252
CYP2C9
the effects of fluvastatin a CYP2C9 inhibitor on losartan pharmacokinetics in healthy volunteers, 418
CYP2D6
nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6(high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs, 567
CYP2E1
effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone, 1177
CYP3A4
intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance, 664
morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios:intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction, 487
nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): inplications for interactions with enzyme-inducing drugs, 567
CYP3A
concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, 1212
hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A, 260
Cystic fibrosis
the pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis, 1242
Cytomegalovirus
pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients, 505

Dapsone
pharmacokinetics of trimetrexate and dapsone in AIDS patients with *pneumocystis* carinii pneumonia, 268
Dextromethorphan
antihyperalgesic effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan in the oral surgery model, 139
DHEA
DHEA and DHEA-S: a review, 327
Digoxin
effect of multiple doses of montelukast as $CysLT_1$ receptor antagonist on digoxin pharmacokinetics in healthy volunteers, 941
Dopamine-1
sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose tolerability study, 471
Dosing regimens
a comparison of two dosing regimens of succimer in children with chronic lead poisoning, 180
Down syndrome
altered clearance of theophylline in children with Down Syndrome: a case series, 359
Drug development
absolute oral versus inhaled bioavailability:significance for inhaled drugs with special reference to inhaled glucocorticoids, 661
assessment of QTc prolongation for noncardiac-related drugs from a drug development perspective, 349
assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues, 1006
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on lableing, 899
first time in human for GV196771:interspecies scaling applied on dose selection, 560
Drug interactions
altered pharmacokinetics of indinavir by novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients, 1085
assessment of potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban, 513
assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues, 1006
coadministration of short-term zolpidem with sertraline in healthy women, 184
the contribution of p-glycoprotein to pharmacokinetic drug-drug interactions, 1203
the effect of azithromycin on the pharmacokinetics of indinavir, 842
the effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, 86
effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin, 847
effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects, 636
the effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline, 855
effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, 495
effect of multiple doses of montelukast a $CysLT_1$ receptor antagonist on digoxin pharmacokinetics in healthy volunteers, 941
effect of troglitazone on the pharmacokinetics of an oral contraceptive agent, 410
effect of venlafaxine on the pharmacokinetics of risperidone, 297
the effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin, 68
the effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers, 418
effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers, 91
erythromycin coadministration increases plasma atorvastatin concentrations, 501
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling, 899
lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion, 1184
lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacody-

namics of steady-state intranasal levocabastine, 76
lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin, 1283
lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults, 945
lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine, 192
pharmacokinetics and adrenal interactions of IL-10 and prednisone in healthy volunteers, 624
the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV and CMV-seropositive patients, 505
rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics, 1189
trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir, 1077

Drug metabolism
concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, 1212
differences in urinary excretion of 6-β hydroxycortisol/cortisol between Asian and Caucasian women, 578
effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone, 1177
effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine, 252
gabapentin does not affect antipyrine clearance, 934
hormonal effects on tirilazad clearance in women:assessment of the role of CYP3A, 260
inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women, 936
intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance, 664
morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction, 487
nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs, 567

Drug monitoring
electronic monitoring of compliance to lipid-lowering therapy in clinic practice, 402

Drug therapy
P-glycoprotein and drug therapy in organ transplantation, 995

Drug trials
are the elderly underrepresented in clinical drug trials?, 1103

Drug use
carbamazepine levels in head hair of patients under long-term treatment: a method to evaluate the history of drug use, 55

Editorial
products approved for marketing during 1998, 439
review and survey of the issues in asthma today, 211

Education
use of a mail-out continuing education article to teach health professionals about drug-induced disease, 1126

Electronic monitoring
electronic monitoring of compliance to lipid-lowering therapy in clinical practice, 402

Enzyme-inducing drugs
nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs, 567

Epilepsy
no effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy, 1070
population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy, 373

Erythromycin
assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromcin and argatroban, 513
erythromycin coadministration increases plasma atorvastatin concentrations, 501
lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine, 76

Erythromycin breath test (EBT)
concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, 1212

Ethnicity
differences in the urinary excretion of 6-β-Hydroxycortisol/cortisol between Asian and Caucasion women, 578
fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects, 155

Etodolac
pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery, 729

Federal Drug Administration
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling, 899

Fenoldopam
sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose tolerability study, 471

Fluoxetine
fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled with mass spectrometry, 1053

Fluvastatin
the effects of fluvastatin, a CYP2C9, inhibitor on losartan pharmacokinetics in healthy volunteers, 418

Food
effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects, 161
the effect of food on the oral bioavailability and pharmacodynamic actions of insulinotropic agent nateglinide in healthy subjects, 172
the effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin), 1155
effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919), 911
lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption, 593

Fosinopril
fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects, 155

Gabapentin
gabapentin does not affect antipyrine clearance, 934

Ganciclovir
effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects, 161
the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients, 505

Gastric ulcers
smoking and gastric ulcers: possible role of nicotine, 448

Gender
no effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy, 1070
open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects, 281

Genistein
clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies, 1248

Geriatric
are the elderly underrepresented in clinical drug trials?, 1103
a comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers, 480

Glucagon
a review of potential caridovascular uses of intravenous glucagon administration, 442

Glucocorticoids
absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids, 661
effects of glucocorticoids and cyclosporine on IL-2 and IκBα mRNA expression in human peripheral blood mononuclear cells, 119
lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline and mycophenolic acid, 125

Granulocyte
pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (Lenograstim) administration, 583

GV196771
first time in human for GV196771: interspecies scaling applied on dose selection, 560

Headache
pharmacodynamics of sumatriptan in

nitroglycerin-induced headache, 17

Hepatocellular diseases
salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases, 366

HIV
altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor: a pharmacokinetic evaluation in HIV-positive patients, 1085

effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects, 161

the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients, 505

pharmacokinetics and tolerability of intravenous trecovirsen (GEM® 91), an antisense phosphorothioate oligonucleotide, in HIV-positve subjects, 47

pharmacokinetics of trimetrexate and dapsone in AIDS patients with *pneumocystic carinii* pneumonia, 268

single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects, 800

HMG CoA Reductase inhibitors
pharmacological effects of HGM CoA reductase inhibitors other than lipoprotein modulation, 111

Human blood mononuclear cells
effects of glucocorticoids and cyclosporine on IL-2 and IκBα mRNA expressions in human peripheral blood mononuclear cells, 119

Hypertension
sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients, 471

Ibuprofen
the safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis, 520

Ifosfamide
risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children, 454

IκBα mRNA
effects of glucocorticoids and cyclosporine on Il-2 and IκBα mRNA expression in human peripheral blood mononuclear cells, 119

IL-2
effects of glucocorticoids and cyclosporine on IL-2 and IκBα mRNA expression in human peripheral blood mononuclear cells, 119

IL-10
pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers, 624

Immunology. *See* **Transplantation**

Indinavir
altered pharmacokinetics of indinavir by novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients, 1085

the effect of azithromycin on the pharmacokinetics of indinavir, 842

effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects, 636

trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir, 1077

Interleukin-10
disposition of recombinant human interleukin-10 in subjects with various degrees of renal function, 1015

Ketoconazole
lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine, 76

Ketoprofen
analegesic efficacy and pharmacokinetics of ketoprofen administed into a surgical site, 131

Lamivudine
lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption, 593

Lamotrigine
population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy, 373

Lansoprazole
lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin, 1283

Lead poisoning
a comparison of two dosing regimens of succimer in children with chronic lead poisoning, 180

Lenograstim
pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration, 583

Linezolid
a pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam, 1277

Lipids
electronic monitoring of compliance to lipid-lowering therapy in clinical practice, 402

Lipoprotein modulation
pharmacological effects of HMG CoA reducatase inhibitors other than lipoprotein modulation, 111

Lornoxicam
efficacy and tolerability of lornoxicam versus tramadol in postoperative pain, 834

Losartan
the effects of fluvastatin, a CYP2C9, inhibitor on losartan pharmacokinetics in healthy volunteers, 418

Lymphocyte suppression
lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid, 125

Medication compliance
limits of confidence in tracer compounds as a means of measuring patient compliance with medication, 1233

Melatonin
feasibility and functionality of OROS® melatonin in healthy subjects, 606

Menstrual cycle
menstrual cycle variability in midazolam pharmacokinetics, 275

Methods
limits of confidence in tracer compounds as a means of measuring patient compliance with medication, 1233

Methylphenidate
population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder, 775

Mibefradil
case report: thabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin, 310

Microbial biofilms
microbial biofilms: their development and significance for medical device–related infections, 887

Midazolam
concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, 1212

intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance, 664

pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam, 1109

Modafinil
a double-blind, placebo-controlled, ascending-dose evaluation of pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers, 30

open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects, 281

Montelukast
effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, 495

effect of multiple doses of montelukast, as $CysLT_1$ receptor antagonist, on digoxin pharmacokinetics in healthy volunteers, 941

montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults, 786

Moricizine
moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implications, 817

Mycophenolic acid
lymphocyte suppresion by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid, 125

Mycophenolic acid protein binding
the effect of renal insufficiency on mycophenolic acid protein binding, 715

N-methyl-D-aspartate
antihyperalgesic effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan in the oral surgery model, 139

Nateglinide
the effect of food on the oral bioavailability and the pharmacodynamic actions of insulinotropic agent nateglinide in healthy subjects, 172

Neoral
a limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients, 166

Nephrotoxicity
risk factors for long-term outcome in ifosfamide-induced nephrotoxicity in children, 454

Nicotine
smoking and gastric ulcers: possible role of nicotine, 448
Nifedipine
rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics, 1189
Nitroglycerin
the pharmacodynamics of sumatriptan in nitroglycerin-induced headache, 17
Nortriptyline E-10-hydroxylation
Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs, 567

Obesity
long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients, 41
Oesclim
comparison of the pharmacokinetics of 17β-estradiol after a single 4-day application of Oesclim®50, Oesclim®100, and Vivelle®0.05 (Menorest®50) transdermal delivery systems, 811
Oral surgery
antihyperalgesic effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan in the oral surgery model, 139
pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery, 729
Orlistat
long-term exposure of orlistat a lipase inhibitor and its metabolites in obese patients, 41
OROS
feasibility and funtionality of OROS® melatonin in healthy subjects, 606
Oxybutynin
pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin, 289

P-glycoprotein
the contribution of P-glycoprotein to pharmacokinetic drug-drug interactions, 1203
P-glycoprotein and drug therapy in organ transplantation, 995
Pantoprazole
lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults, 945
Paroxetine
lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine, 192
Paroxetine therapy
severe life-threatening hyponatremia during paroxetine therapy, 1290
Pediatrics
altered clearance of theophylline in children with down syndrome, 359
a comparision of two dosing regimens of succimer in children with chronic lead poisoning, 180
montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults, 786
no effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy, 1070
the pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis, 1242
population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder, 775
risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children, 454
salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases, 366
Pentoxifylline
lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid, 125
Pharmacodynamics
the effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, 86
the effect of food on oral bioavailability and pharmacodynamic actions of insulinotropic agent nateglinide in healthy subjects, 172
the effects of aetaminophen on pharmacokinetics and pharmacodynamics of warfarin, 68
fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects, 155
lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine, 76
pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam, 1109
pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride, 1263
the pharamacodynamics of sumatriptan in nitroglycerin-induced headache, 17
Pharmacokinetics
the effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin, 68
analgesic efficacy and pharmacokinetcs of ketoprofen administeded into a surgical site, 131
azimilide pharmacokenetics following intravenous and oral adminstration of a solution and capsule formulation, 1272
bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design, 1032
buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations, 619
comparison of the pharmacokinetics of 17β-estradiol after single 4-day application of Oesclim®50, Oesclim®100, and Vivelle® 0.05 (Menorest®50) transdermal delivery systems, 811
comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in health elderly and young volunteers, 480
disposition of recombinant human interleukin-10 in subjects with various degrees of renal function, 1015
a double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers, 30
the effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin), 1155
effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919), 911
the effect of pharmacokinetically guided acute intravenous testosterone administration on electrocardiographic and blood pressure variables, 1038
the effect of renal insufficiency on mycophenolic acid protein binding, 715
effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers, 91
feasibility and functionality of OROS® melatonin in healthy subjects, 606
fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry, 1053
fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects, 155
lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine, 76
lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine, 192
lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption, 593
menstrual cycle variability in midazolam pharmacokinetics, 275
moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implicaitons, 817
multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers, 703
open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects, 281
pharmacokinetic changes of theophylline and amikacin through the menstrual cycle in healthy women, 1256
a pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam, 1277
pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam, 1109
a pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration, 695
pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin, 289
pharmacokinetics of calcium absorption from two commercial calcium supplements, 1151
pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance, 147
pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal car-

cinomatosis, 394
pharmacokinetics of clinafloxacin enantiomers in humans, 1143
the pharmacokinetics of extended-release formulations of calcium antagnoists and of amlodipine in subjects with different gastrointestinal transit times, 1021
pharmacokinetics of intravenous alendronate, 385
pharmacokinetics and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration, 583
pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects, 685
pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride, 1263
pharmacokinetics and pharmacodynamics of sibrafiban an orally administered IIb/IIIa antagonist in patients with acute coronary syndrome, 675
pharmacokinetics of a recombinant modified amino terminal fragment of bactericidal/permeability-increasing protein ($rBPI_{21}$)in healthy volunteers, 1169
pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients, 1136
pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers, 1044
pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers, 462
pharmacokinetics of trimetrexate and dapsone in AIDS patients with *pneumocystis carinii* pneumonia, 268
population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy, 373
rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure, 927
single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults, 613
single-dose oral pharacokinetics of three formulations of thalidomide in healthy male volunteers, 1162
single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects, 800
steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites, 920
studies on the pharmacokinetics and pharmacodynamics of Propranolol in hyperlipidemia, 826
sustained hemodynamic effects on the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study, 471
systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream, 805
pharamacokinetics and tolerability of intravenous trecovirsen (GEM*91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects, 47

Phenytoin
lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin, 1283

Pleconaril
single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults, 613

Pneumonia
pharmacokinetics of trimetrexate and dapsone in AIDS patients with *pneumocystis carinii* pneumonia, 268

Pravastatin
the effect of converting from pravastatin to simvastatin on pharmacodynamics of warfarin, 86

Prednisone
pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers, 624

Propranolol
studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia, 826

Psychopharmacology
the frequency of caffeine withdrawl in a population-based survey and in a controlled, blinded pilot experiment, 1221

QTc
assessment of QTc prolongation for noncardiac-related drugs from a drug development perspective, 349

Rabeprazole
rabeprazole: pharmacokinetics and tolerability in patients with stable end-stage renal failure, 927

Raloxifene
raloxifene, a new selective estrogen receptor modulator, 767

Ranitidine
the pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis, 1242

Rapamycin
the effect of a high-fat meal on oral bioavailability of the immunosuppressant sirolimus, 1155

Renal functions
disposition of recombinant human interleukin-10 in subjects with various degrees of renal function, 1015
the effect of renal insufficiency on mycophenolic acid protein binding, 715
pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than low creatinine clearance, 147
rabeprazole: pharmacokinetics and tolerability in patients with stable end-stage renal failure, 927

Renal transplantation
a limited sampling strategy for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients, 166

Rhabdomyolysis
case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin, 310

Rifampin
effects on rifampin on tacrolimus pharmacokinetics in healthy volunteers, 91

Riluzole
a comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers, 480

Risperidone
effect of venlafaxine on the pharmacokinetics of risperidone, 297

Rizatriptan
lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine, 192

Rolipram
lymphocyte suppression by rolipram with other immunosuppressive drugs, 794

Rosiglitazone
rosiglitazone has no clinically significant effect on nifedipine pharmokinetics, 1189

Safety
multiple-dose pharmacokinetics safety and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers, 703
the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients, 505
pharmacokinetics, safety, and tolerability of single intravenous infusions of adenosine agonist, AMP 579, in healthy male volunteers, 1044
pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers, 462
the safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis, 520

SangCya
a limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients, 166

Schizophrenia
clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia, 721

Sertraline
coadministration of short-term zolpidem with sertraline in healthy women, 184

Sibrafiban
pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome, 675

Simvastatin
case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin, 310
the effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, 86

Sirolimus
the effect of a high-fat meal on oral bioavailability of the immunosuppressant sirolimus (rapamycin), 1155

six6-B-hydroxycortisol
differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between Asian and Caucasian women, 578

Smoking
smoking and gastric ulcers: the possible role of nicotine, 448

Stavudine
the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropostive patients, 505

Succimer
a comparison of two dosing regimens of succimer in children with chronic lead poisoning, 180

Sulfamethoxazole
trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir, 1077

Sumatriptan
the pharmacodynamics of sumatriptan in nitroglycerin-induced headache, 17

Tacrolimus
bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design, 1032

effects of rifampin on tacrolimus pharmacolinetics in health volunteers, 91

lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline and mycophenolic acid, 125

Tegaserod
effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919), 911

Testosterone
the effect of pharmacokinetically guided acute intravenous testosterone administration on electrocardiographic and blood pressure variables, 1038

Thalidomide
single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers, 1162

Theophylline
altered clearance of theophylline in children with down syndrome: a case series, 359

effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects, 636

the effect of low-dose cimetidine (200 mg twice daily) on the pharacokinetics of theophylline, 855

pharmacokinetic changes of theophylline and amikacin through the menstrual cycle in healthy women, 1256

Tirilazad
hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A, 260

Tolerability
efficacy and tolerability of lornoxicam versus tramadol in postoperative pain, 834

multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers, 703

pharmacokinetics, safety, and tolerability of single intravenous infusions of adenosine agonist, AMP 579, in healthy male volunteers, 1044

pharmacokinetics and tolerability of intravenous trecovirsen (GEM®91) an antisense phosphorothioate oligonucleotide in HIV-positive subjects, 47

rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure, 927

sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study, 471

Tracer compounds
limits of confidence in tracer compounds as a means of measuring patient compliance with medication, 1233

Tramadol
efficacy and tolerability of lornoxicam versus tramadol in postoperative pain, 834

Transplantation
lymphocyte suppression by rolipram with other immunosuppressive drugs, 794

P-glycoprotein and drug therapy in organ transplantation, 995

Transportation
a limited sampling strategy for the estimation of 12-hour SangCya and Neoral ACUs in renal transplant recipients, 166

lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid, 125

Trecovirsen
pharmacokinetics and tolerability of intravenous trecovirsen (GEM®91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects, 47

Triamcinolone acetonide
a pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration, 695

Triazolam
pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam, 1109

Trimethoprim
trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir, 1077

Trimetrexate
pharmacokinetics of trimetrexate and dapsone in AIDS patients with *pneumocystis carinii* pneumonia, 268

Troglitazone
effect of troglitazone on the pharmacokinetics of an oral contraceptive agent, 410

steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites, 920

Valganciclovir
single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects, 800

Valproic acid
no effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy, 1070

Venlafaxine
effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine, 252

effect of venlafaxine on the pharmacokenetics of risperidone, 297

Vesnarinone
effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone, 1177

Vivelle
comparison of the pharmacokinetics of 17β-estradiol after a single 4-day application of Oesclim®50, Oesclim®100, and Vivelle®0.05 (Menorest®50) transdermal delivery system, 811

Warfarin
the effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, 86

effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin, 847

effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers, 495

the effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin, 68

Women
coadministration of short-term zolpidem with sertraline in healthy women, 184

comparison of the pharmacokenetics of 17β-estradiol after a single 4-day application of Oesclim®50, Oesclim®100, and Vivelle®0.05 (Menorest®50) transdermal delivery systems, 811

differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between Asian and Caucasian women, 578

effect of troglitazone on the pharmacokinetics of an oral contraceptive agent, 410

hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A, 260

inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women, 936

menstrual cycle variability in midazolam pharmacokinetics, 275

pharmacokinetic changes of theophylline and amikacin through the menstrual cycle in healthy women, 1256

pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients, 1136

raloxifene, a new selective estrogen receptor modulator, 767

rapid disappearance of zaleplon from breast milk after oral administration to lactating women, 670

systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream, 805

Z-321
pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers, 462

Zalcitabine
the pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients, 505

Zaleplon
rapid disappearance of zaleplon from breast milk after oral administration to lactating women, 670

Zidovudine
lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption, 593

Zolpidem
coadministration of short-term zolpidem with sertraline in healthy women, 184